BlockBeats News, December 2nd, According to market sources, Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies.
Previously reported, Hyperliquid Strategies plans to raise up to $1 billion, intended to be used to purchase HYPE, etc.
